Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register

Katerina Chatzidionysiou, Johan Askling, Jonas Eriksson, Lars Erik Kristensen, Ronald van Vollenhoven

Research output: Contribution to journalArticlepeer-review

50 Citations (SciVal)

Abstract

Background Switching to a second tumour necrosis factor inhibitor (TNFi) after discontinuation of a first in rheumatoid arthritis (RA) is a common strategy. The reason for the switch from the first TNFi could potentially influence the response to therapy. Data on direct comparisons between TNFi after switching are limited. Methods The national Swedish register was used. RA patients who switched to a second TNFi (infliximab, etanercept or adalimumab) after failure of a TNFi as first-ever biologic were identified. Effectiveness of treatment was compared across the three drugs according to the first TNFi used, the reason for discontinuing and the drug survival. Drug survival across TNFi used as second biologic was compared. Results Half of all patients starting infliximab, adalimumab or etanercept during the period 2005-2012 discontinued treatment for various reasons. Of these patients, a third switched within 2 months to a second TNFi (infliximab, etanercept or adalimumab). Around 35% of all patients achieved low disease activity or remission at 6 months. Regarding the switching strategy, best results were observed among patients who switched from infliximab to etanercept because of (secondary) inefficacy. Etanercept as second TNFi was associated with longer drug survival compared with infliximab. Conclusions Switching to a second TNFi after the failure of the first may lead to good clinical results. The inter-drug differences in drug survival on the second TNFi mirror those reported previously for the first TNFi, suggesting that these differences are not solely due to channelling bias.
Original languageEnglish
Pages (from-to)890-896
JournalAnnals of the Rheumatic Diseases
Volume74
Issue number5
DOIs
Publication statusPublished - 2014

Subject classification (UKÄ)

  • Rheumatology and Autoimmunity

Fingerprint

Dive into the research topics of 'Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register'. Together they form a unique fingerprint.

Cite this